Molecule
Aflibercept is a vascular endothelial growth factor inhibitor indicated for the treatment of eYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Aflibercept for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD). Macular Edema Following Retinal Vein Occlusion (RVO). Diabetic Macular Edema (DME). Diabetic Retinopathy (DR). Retinopathy of Prematurity (ROP)
Source: US FDA prescribing information
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
Source: US FDA prescribing information
Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for EYLEA is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.
Source: US FDA prescribing information
Ocular or periocular infection. Active intraocular inflammation. Hypersensitivity Ocular or Periocular Infections EYLEA is contraindicated in patients with ocular or periocular infections.
Source: US FDA prescribing information
Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. In infants with ROP, treatment with EYLEA will necessitate extended periods of ROP monitoring. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.
Source: US FDA prescribing information
The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion Increase in intraocular pressure Thromboembolic events The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Source: US FDA prescribing information
Store in the original carton until time of use to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Aflibercept, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Eylea 2 mg/0.05 mL injectionIntravitreal | Regeneron Pharmaceuticals | US FDA | Available on request |
| Eylea HD 8 mg/0.07 mL injectionIntravitreal | Regeneron Pharmaceuticals | US FDA | Available on request |
| Pavblu 2 mg/0.05 mL injectionIntravitreal | Amgen | US FDA | Available on request |
| Ahzantive 2 mg/0.05 mL injectionIntravitreal Cold chain | Valorum Biologics | US FDA | Available on request |
| Yesafili 2 mg/0.05 mL injectionIntravitreal Cold chain | Biocon BiologicsIndia | US FDA | Available on request |
| Enzeevu 2 mg/0.05 mL injectionIntravitreal Cold chain | Sandoz | US FDA | Available on request |
| Zaltrap 100 mg/4 mL injectionIntravenous Cold chain | Sanofi-Aventis | US FDA | Available on request |
| Zaltrap 200 mg/8 mL injectionIntravenous Cold chain | Sanofi-Aventis | US FDA | Available on request |
7 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Aflibercept in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Aflibercept and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Biocon Biologics.
The catalogue lists 7 brand names for Aflibercept, including Ahzantive, Enzeevu, Eylea, Eylea HD, Pavblu, Yesafili, Zaltrap.
Yes. The US FDA first approved Aflibercept on 18 November 2011, according to Drugs@FDA.
Yes. Aflibercept has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Aflibercept must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Aflibercept is classified under ATC code L01XX44 (Aflibercept).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.